{"id":39450,"date":"2026-09-23T11:17:22","date_gmt":"2026-09-23T11:17:22","guid":{"rendered":"https:\/\/itbusinesstoday.com\/?p=39450"},"modified":"2026-09-23T11:17:22","modified_gmt":"2026-09-23T11:17:22","slug":"ionis-and-roche-report-progress-for-sefaxersen","status":"publish","type":"post","link":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/","title":{"rendered":"\u30a2\u30a4\u30aa\u30cb\u30b9\u793e\u3068\u30ed\u30b7\u30e5\u793e\u304c\u30bb\u30d5\u30a1\u30af\u30bb\u30eb\u30bb\u30f3\u306e\u958b\u767a\u9032\u6357\u3092\u5831\u544a\u3057\u305f"},"content":{"rendered":"

Ionis Pharmaceuticals<\/a> \u307e\u305f\u3001\u30ed\u30b7\u30e5\u306f\u3001\u539f\u767a\u6027\u514d\u75ab\u30b0\u30ed\u30d6\u30ea\u30f3A\u814e\u75c7\uff08IgAN\uff09\u306e\u6210\u4eba\u60a3\u8005\u3092\u5bfe\u8c61\u306b\u30bb\u30d5\u30a1\u30af\u30bb\u30eb\u30bb\u30f3\u3092\u8a55\u4fa1\u3059\u308b\u7b2c3\u76f8IMAgINATION\u8a66\u9a13\u306b\u3064\u3044\u3066\u3001\u6709\u671b\u306a\u4e2d\u9593\u7d50\u679c\u3092\u767a\u8868\u3057\u3066\u3044\u308b\u3002.<\/p>

\u7b2c37\u9031\u307e\u3067\u306b\u3001\u30bb\u30d5\u30a1\u30af\u30bb\u30eb\u30bb\u30f3\u306f\u8a66\u9a13\u306e\u4e3b\u8981\u8a55\u4fa1\u9805\u76ee\u3092\u9054\u6210\u3057\u3001\u30d7\u30e9\u30bb\u30dc\u7fa4\u3068\u6bd4\u8f03\u3057\u3066\u30bf\u30f3\u30d1\u30af\u5c3f\u306e\u6e1b\u5c11\u306b\u304a\u3044\u3066\u3001\u7d71\u8a08\u7684\u6709\u610f\u6027\u304a\u3088\u3073\u81e8\u5e8a\u7684\u610f\u7fa9\u3092\u793a\u3057\u305f\u3002\u3053\u308c\u306f\u300124\u6642\u9593\u5c3f\u4e2d\u30bf\u30f3\u30d1\u30af\/\u30af\u30ec\u30a2\u30c1\u30cb\u30f3\u6bd4\uff08UPCR\uff09\u3092\u7528\u3044\u3066\u6e2c\u5b9a\u3055\u308c\u305f\u3002 \u30bf\u30f3\u30d1\u30af\u5c3f\u306f\u814e\u6a5f\u80fd\u969c\u5bb3\u306e\u4e3b\u8981\u306a\u30de\u30fc\u30ab\u30fc\u3067\u3042\u308a\u3001\u3053\u306e\u30d0\u30a4\u30aa\u30de\u30fc\u30ab\u30fc\u306e\u6e1b\u5c11\u306f\u814e\u6a5f\u80fd\u306e\u7dad\u6301\u3068\u95a2\u9023\u3057\u3066\u3044\u308b\u3002.<\/p>

\u30bb\u30d5\u30a1\u30af\u30bb\u30eb\u30bb\u30f3\u306f\u3001\u67081\u56de\u306e\u76ae\u4e0b\u6295\u4e0e\u3067\u81ea\u5df1\u6ce8\u5c04\u304c\u53ef\u80fd\u306a\u85ac\u5264\u3068\u3057\u3066\u7814\u7a76\u304c\u9032\u3081\u3089\u308c\u3066\u3044\u308b\u3002\u5b89\u5168\u6027\u304a\u3088\u3073\u5fcd\u5bb9\u6027\u306b\u95a2\u3059\u308b\u30c7\u30fc\u30bf\u306f\u3053\u308c\u307e\u3067\u306e\u77e5\u898b\u3068\u4e00\u81f4\u3057\u3066\u304a\u308a\u3001\u4e21\u793e\u306b\u3088\u308b\u65b0\u305f\u306a\u5b89\u5168\u6027\u306e\u554f\u984c\u306f\u78ba\u8a8d\u3055\u308c\u306a\u304b\u3063\u305f\u3002.<\/p>

\u3053\u3061\u3089\u3082\u304a\u8aad\u307f\u304f\u3060\u3055\u3044\uff1a FACEDUO\u304c\u300c\u8a8d\u77e5\u75c7\u306e\u8996\u70b9\u300d\u306b\u95a2\u3059\u308b\u65b0\u30b3\u30f3\u30c6\u30f3\u30c4\u3092\u516c\u958b\u3057\u305f<\/a><\/p>

\u3053\u306e\u7814\u7a76\u306f\u307e\u3060\u7d42\u308f\u3063\u3066\u3044\u306a\u3044\u3002IMAgINATION\u8a66\u9a13\u306f\u76f2\u691c\u8a66\u9a13\u3068\u3057\u3066\u7d99\u7d9a\u3055\u308c\u3001\u6b21\u306e\u7126\u70b9\u306f2\u5e74\u9593\u306b\u308f\u305f\u308b\u814e\u6a5f\u80fd\u3068\u306a\u308b\u3002\u7814\u7a76\u8005\u3089\u306f105\u9031\u76ee\u306b\u63a8\u7b97\u7cf8\u7403\u4f53\u6ffe\u904e\u7387\uff08eGFR\uff09\u3092\u8a55\u4fa1\u3059\u308b\u4e88\u5b9a\u3060\u3002\u30ed\u30b7\u30e5\u3068\u30a2\u30a4\u30aa\u30cb\u30b9\u306f\u3001\u8fd1\u3005\u958b\u50ac\u3055\u308c\u308b\u533b\u5b66\u4f1a\u8b70\u3067\u767a\u8868\u3092\u884c\u3046\u4e88\u5b9a\u3060\u3002.<\/p>

IgA\u814e\u75c7\uff08\u30d9\u30eb\u30ac\u30fc\u75c5\u3068\u3082\u547c\u3070\u308c\u308b\uff09\u306f\u3001\u9032\u884c\u6027\u306e\u814e\u81d3\u306e\u81ea\u5df1\u514d\u75ab\u75be\u60a3\u306e\u4e00\u4f8b\u3067\u3042\u308b\u3002IgA\u814e\u75c7\u60a3\u8005\u306e50\uff05\u306f\u3001\u7d0420\u5e74\u5f8c\u306b\u672b\u671f\u814e\u4e0d\u5168\u306b\u81f3\u308a\u3001\u900f\u6790\u3084\u79fb\u690d\u304c\u5fc5\u8981\u306b\u306a\u308b\u5834\u5408\u304c\u3042\u308b\u3002 \u3053\u306e\u75be\u60a3\u306f\u4e00\u822c\u7684\u306b40\u6b73\u672a\u6e80\u3067\u767a\u75c7\u3057\u3001\u5e74\u9593\u767a\u75c7\u7387\u306f\u4eba\u53e3100\u4e07\u4eba\u3042\u305f\u308a25\u4eba\u3092\u8d85\u3048\u308b\u3002.<\/p>

\u30ed\u30b7\u30e5\u306f\u3001\u88dc\u4f53\u4ecb\u5728\u6027\u75be\u60a3\u306e\u6cbb\u7642\u85ac\u3068\u3057\u3066\u3001\u30a2\u30a4\u30aa\u30cb\u30b9\u793e\u304b\u3089\u30bb\u30d5\u30a1\u30af\u30bb\u30eb\u30bb\u30f3\u306e\u30e9\u30a4\u30bb\u30f3\u30b9\u3092\u53d6\u5f97\u3057\u305f\u3002\u672c\u5951\u7d04\u306b\u57fa\u3065\u304d\u3001\u30a2\u30a4\u30aa\u30cb\u30b9\u793e\u306f\u524d\u6255\u3044\u91d1\u3001\u30e9\u30a4\u30bb\u30f3\u30b9\u6599\u3001\u958b\u767a\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u652f\u6255\u3044\u3092\u53d7\u3051\u53d6\u308a\u3001\u4eca\u5f8c\u3082\u898f\u5236\u5f53\u5c40\u306e\u627f\u8a8d\u304a\u3088\u3073\u8ca9\u58f2\u306b\u95a2\u3059\u308b\u30de\u30a4\u30eb\u30b9\u30c8\u30fc\u30f3\u652f\u6255\u3044\u306e\u5bfe\u8c61\u3068\u306a\u308b\u307b\u304b\u3001\u30bb\u30d5\u30a1\u30af\u30bb\u30eb\u30bb\u30f3\u306e\u7d14\u58f2\u4e0a\u9ad8\u306b\u57fa\u3065\u304f\u6bb5\u968e\u7684\u306a\u30ed\u30a4\u30e4\u30ea\u30c6\u30a3\u3092\u53d7\u3051\u53d6\u308b\u6a29\u5229\u3092\u6709\u3057\u3066\u3044\u308b<\/p>","protected":false},"excerpt":{"rendered":"

Ionis Pharmaceuticals and Roche have revealed encouraging interim results from the Phase 3 IMAgINATION trial evaluating sefaxersen in adult patients with primary immunoglobulin A nephropathy, or IgAN.By week 37, sefaxersen had met the trial’s primary objective, achieving statistical significance as well as clinical relevance in the reduction in proteinuria when compared to the placebo group. This was measured using the 24-hour urine protein-to-creatinine ratio or UPCR. Proteinuria is a major marker of renal dysfunction, and the reduction in this biomarker is associated with kidney function preservation.Sefaxersen is being researched as a once-a-month subcutaneous medication that can be self-injected. Safety and tolerability data was in line with previous findings, and no […]<\/p>\n","protected":false},"author":7,"featured_media":39470,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"wprm-recipe-roundup-name":"","wprm-recipe-roundup-description":"","postBodyCss":"","postBodyMargin":[],"postBodyPadding":[],"postBodyBackground":{"backgroundType":"classic","gradient":""},"footnotes":""},"categories":[89,207,237],"tags":[15802,15806,15803,15805,15804],"ppma_author":[572],"class_list":["post-39450","post","type-post","status-publish","format-standard","has-post-thumbnail","category-health-tech","category-international","category-news","tag-autoimmune-disorder","tag-ionis","tag-nephropathy","tag-roche","tag-sefaxersen"],"yoast_head":"\nSefaxersen Delivers Positive Phase 3 Data<\/title>\n<meta name=\"description\" content=\"Ionis and Roche report positive Phase 3 results for Sefaxersen as a potential treatment for IgA nephropathy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sefaxersen Delivers Positive Phase 3 Data\" \/>\n<meta property=\"og:description\" content=\"Ionis and Roche report positive Phase 3 results for Sefaxersen as a potential treatment for IgA nephropathy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/itbusinesstoday.com\/ja\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/\" \/>\n<meta property=\"og:site_name\" content=\"itbusinesstoday\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-23T11:17:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/09\/Ionis-announces-positive-interim-data-from-partner-Roches-Phase-3-IMAgINATION-study-in-IgA-nephropathy-IgAN.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"ITBT StaffWriter\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u57f7\u7b46\u8005\" \/>\n\t<meta name=\"twitter:data1\" content=\"ITBT StaffWriter\" \/>\n\t<meta name=\"twitter:label2\" content=\"\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u5206\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sefaxersen Delivers Positive Phase 3 Data","description":"Ionis and Roche report positive Phase 3 results for Sefaxersen as a potential treatment for IgA nephropathy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/","og_locale":"ja_JP","og_type":"article","og_title":"Sefaxersen Delivers Positive Phase 3 Data","og_description":"Ionis and Roche report positive Phase 3 results for Sefaxersen as a potential treatment for IgA nephropathy.","og_url":"https:\/\/itbusinesstoday.com\/ja\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/","og_site_name":"itbusinesstoday","article_published_time":"2026-09-23T11:17:22+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/09\/Ionis-announces-positive-interim-data-from-partner-Roches-Phase-3-IMAgINATION-study-in-IgA-nephropathy-IgAN.webp","type":"image\/webp"}],"author":"ITBT StaffWriter","twitter_card":"summary_large_image","twitter_misc":{"\u57f7\u7b46\u8005":"ITBT StaffWriter","\u63a8\u5b9a\u8aad\u307f\u53d6\u308a\u6642\u9593":"2\u5206"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/itbusinesstoday.com\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/#article","isPartOf":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/"},"author":{"name":"ITBT StaffWriter","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15"},"headline":"Ionis and Roche Report Progress for Sefaxersen","datePublished":"2026-09-23T11:17:22+00:00","mainEntityOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/"},"wordCount":281,"publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/09\/Ionis-announces-positive-interim-data-from-partner-Roches-Phase-3-IMAgINATION-study-in-IgA-nephropathy-IgAN.webp","keywords":["autoimmune disorder","Ionis","nephropathy","Roche","Sefaxersen"],"articleSection":["Health Tech","International","News"],"inLanguage":"ja"},{"@type":"WebPage","@id":"https:\/\/itbusinesstoday.com\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/","url":"https:\/\/itbusinesstoday.com\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/","name":"Sefaxersen Delivers Positive Phase 3 Data","isPartOf":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website"},"primaryImageOfPage":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/#primaryimage"},"image":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/#primaryimage"},"thumbnailUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/09\/Ionis-announces-positive-interim-data-from-partner-Roches-Phase-3-IMAgINATION-study-in-IgA-nephropathy-IgAN.webp","datePublished":"2026-09-23T11:17:22+00:00","description":"Ionis and Roche report positive Phase 3 results for Sefaxersen as a potential treatment for IgA nephropathy.","breadcrumb":{"@id":"https:\/\/itbusinesstoday.com\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/itbusinesstoday.com\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/"]}]},{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/#primaryimage","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/09\/Ionis-announces-positive-interim-data-from-partner-Roches-Phase-3-IMAgINATION-study-in-IgA-nephropathy-IgAN.webp","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2026\/09\/Ionis-announces-positive-interim-data-from-partner-Roches-Phase-3-IMAgINATION-study-in-IgA-nephropathy-IgAN.webp","width":1200,"height":800,"caption":"Ionis"},{"@type":"BreadcrumbList","@id":"https:\/\/itbusinesstoday.com\/health-tech\/ionis-and-roche-report-progress-for-sefaxersen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/itbusinesstoday.com\/"},{"@type":"ListItem","position":2,"name":"Ionis and Roche Report Progress for Sefaxersen"}]},{"@type":"WebSite","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#website","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","description":"","publisher":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#organization","name":"\u30a4\u30c3\u30c8\u30d3\u30b8\u30cd\u30b9\u30c8\u30a5\u30c7\u30a4","url":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Asset-1.png","width":663,"height":275,"caption":"itbusinesstoday"},"image":{"@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/itbusinesstoday-68b209.ingress-baronn.ewp.live\/#\/schema\/person\/94fb575e469aff25a4b938814d050f15","name":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc","image":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png90b3cb23d1d9c08733d969d29ea2d30d","url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","contentUrl":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","caption":"ITBT StaffWriter"},"description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002","sameAs":["https:\/\/itbusinesstoday.com\/"],"url":"https:\/\/itbusinesstoday.com\/ja\/author\/itbt-staffwriter\/"}]}},"authors":[{"term_id":572,"user_id":7,"is_guest":0,"slug":"itbt-staffwriter","display_name":"ITBT StaffWriter","avatar_url":{"url":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png","url2x":"https:\/\/itbusinesstoday.com\/wp-content\/uploads\/2025\/01\/Favicon-1.png"},"author_category":"","first_name":"ITBT","last_name":"StaffWriter","user_url":"https:\/\/itbusinesstoday.com\/","job_title":"","description":"ITBT\u30b9\u30bf\u30c3\u30d5\u30e9\u30a4\u30bf\u30fc\u306f\u3001IT Business Today\u306e\u793e\u5185\u5bc4\u7a3f\u8005\u3067\u3001\u30bf\u30a4\u30e0\u30ea\u30fc\u306a\u30cb\u30e5\u30fc\u30b9\u3068QuickBytes\u306e\u914d\u4fe1\u3092\u62c5\u5f53\u3057\u3066\u3044\u307e\u3059\u3002IT\u3001\u30cf\u30a4\u30c6\u30af\u3001\u4f01\u696d\u30bd\u30ea\u30e5\u30fc\u30b7\u30e7\u30f3\u306e\u6700\u65b0\u52d5\u5411\u3092\u30ab\u30d0\u30fc\u3057\u3001\u7c21\u6f54\u3067\u30a4\u30f3\u30d1\u30af\u30c8\u306e\u3042\u308b\u6700\u65b0\u60c5\u5831\u3092\u8aad\u8005\u306b\u63d0\u4f9b\u3057\u3066\u3044\u307e\u3059\u3002"}],"_links":{"self":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/39450","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/comments?post=39450"}],"version-history":[{"count":1,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/39450\/revisions"}],"predecessor-version":[{"id":39451,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/posts\/39450\/revisions\/39451"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media\/39470"}],"wp:attachment":[{"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/media?parent=39450"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/categories?post=39450"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/tags?post=39450"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/itbusinesstoday.com\/ja\/wp-json\/wp\/v2\/ppma_author?post=39450"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}